Appendix A

Claim Amendments

- 1. (Currently amended) Pharmacologically Approximately Approximately amended) Pharmacologically compatible metal salt of appridin-2-ylmethylsulphinyl-1H-benzimidazole salts of pyridin-2-ylmethylsulphinyl-1H-benzimidazoles with H+/K+-ATPase-inhibitory activity, in which at least one positive charge equivalent of [[the]] approximately metal ion is counterbalanced by a hydroxyl ion, and hydrates or a hydrate thereof.
- 2. (Currently amended) Pharmacologically pharmacologically compatible metal salt [[salts]] according claim 1, in which the pyridin-2-ylmethylto sulphinyl-1H-benzimidazole pyridin-2-ylmethylsulphinyl-1H-benzimidazoles with H+/K+-ATPase-inhibitory activity is selected from the group consisting of pantoprazole, omeprazole, lansoprazole, rabeprazole, tenatoprazole, (R)-pantoprazole, (S)-pantoprazole, (R)omeprazole, (S)-omeprazole, (R)-lansoprazole, (S)-lansoprazole, (R)-rabeprazole, (S)-rabeprazole, (R)tenatoprazole, and tenatoprazole, (R) -- and-

pantoprazole, (R) and (S) -omeprazole, (R) and (S) -lansoprazole, (R) and (S) -rabeprazole and (R) and (S) -tenatoprazole, and hydrates thereof.

3. (Currently amended) Pharmacologically \underline{A} pharmacologically compatible metal \underline{salt} [[salts]] according to claim 1, characterized by the general formula 1

 $[Me]_{x}[PPI]_{y}[OH]_{z}$ (1)

in which

Me is a pharmacologically acceptable two-valued metal ion,

PPI is a compound selected from the group consisting of

pantoprazole, omeprazole, lansoprazole, rabeprazole,

[[and]] tenatoprazole and their enantiomers,

OH is a hydroxyl ion,

X is a positive, whole number from 1 to 3,

Y is a positive, whole number from 1 to 5 and Z is a positive, whole number from 1 to 5, whereby the equation (Y + Z) = 2X applies, and hydrates or a hydrate thereof.

4. (Currently amended) Pharmacologically \underline{A} pharmacologically compatible metal salt [[salts]] according to claim 1, characterized by the general formula 1 of claim 3,

$[Me]_X[PPI]_Y[OH]_Z$ (1)

in which

Me is a pharmacologically acceptable two-valued metal ion selected from the group consisting of magnesium, calcium and zinc,

PPI is a compound selected from the group consisting of pantoprazole, omeprazole, lansoprazole, rabeprazole, [[and]] tenatoprazole and their enantiomers,

OH is a hydroxyl ion,

X is the number 1 or 2,

Y is a positive, whole number from 1 to 3 and Z is a positive, whole number from 1 to 3,

whereby the equation (Y + Z) = 2X applies, and hydrates or a hydrate thereof.

5. (Currently amended) Pharmacologically A pharmacologically compatible metal salt [[salts]] according

to claim 1, characterized by the general formula 1 $\frac{1}{1}$ of claim $\frac{1}{3}$,

$[Me]_{x}[PPI]_{y}[OH]_{z}$ (1)

in which

Me is magnesium,

PPI is a compound selected from the group consisting of pantoprazole, (R)-pantoprazole and (S)-pantoprazole,

X is the number 1 or 2,

OH is a hydroxyl ion,

Y is the number 1 or 3 and

Z is the number 1 or 3,

whereby the equation (Y + Z) = 2X applies, and hydrates or a hydrate thereof.

6. (Currently amended) Pharmacologically \underline{A} pharmacologically compatible metal salt [[salts]] according to claim 1, characterized by the general formula 1 of claim 3,

$[Me]_{x}[PPI]_{y}[OH]_{z} \qquad (1)$

in which

Me is magnesium,

PPI is (S)-pantoprazole,

OH is a hydroxyl ion,

X is the number 1 or 2,

Y is the number 1 or 3 and

Z is the number 1 or 3,

whereby the equation (Y + Z) = 2X applies, and hydrates or a hydrate thereof.

- 7. (Currently amended) Pharmacologically A pharmacologically compatible metal salt according to claim 1, which is Mg[Pantoprazole]OH, and hydrates or a hydrate thereof.
- 8. (Currently amended) Pharmacologically Appharmacologically compatible metal salt according to claim 1, which is Mg[(S)-Pantoprazole]OH, and hydrates or aphydrate thereof.
- 9. (Currently amended) Pharmacologically $\underline{\underline{A}}$ pharmacologically compatible metal salt according to claim

- 1, which is $Mg_2[Pantoprazole]_3OH$, and hydrates or a hydrate thereof.
- 10. (Currently amended) Pharmacologically A pharmacologically compatible metal salt according to claim 1, which is $Mg_2[(S)-Pantoprazole]_3OH$, and hydrates or a hydrate thereof.
- 11. 12. (Canceled)
- 13. (New) A pharmaceutical composition comprising a pharmacologically compatible metal salt according claim 1 or a hydrate thereof and a pharmaceutically acceptable auxiliary.
- 14. (New) A method of treating a gastrointestinal disorder in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a pharmacologically compatible metal salt according to claim 1 or a hydrate thereof.